Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 9/20 | 0.44 |
| ▸ | UBA3 | Q8TBC4 | 9/20 | 0.44 |
| ▸ | ATG7 | O95352 | 7/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.36 |
| ▸ | UBA7 | P41226 | 1/20 | 0.36 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1796471 | 0.92 | NAE1 (0.47) | NAE1UBA3ATG7CA2UBA6 | |
| SCHEMBL23080273 | 0.80 | CA2 (0.55) | NAE1UBA3ATG7CA2 | |
| SCHEMBL1795319 | 0.80 | CA2 (0.55) | NAE1UBA3ATG7CA2 | |
| SCHEMBL1795272 | 0.76 | ATG7 (0.47) | NAE1UBA3ATG7CA2UBA6 | |
| SCHEMBL5318335 | 0.76 | ATG7 (0.47) | NAE1UBA3ATG7CA2UBA6 | |
| SCHEMBL1800449 | 0.75 | RXFP1 (0.61) | NAE1UBA3ATG7CA2UBA6 | |
| SCHEMBL1795396 | 0.75 | ATG7 (0.67) | NAE1UBA3ATG7CA2UBA6 | |
| SCHEMBL17889811 | 0.75 | ATG7 (0.67) | NAE1UBA3ATG7CA2UBA6 | |
| SCHEMBL23080288 | 0.75 | ATG7 (0.46) | NAE1UBA3ATG7CA2UBA6 | |
| SCHEMBL18630444 | 0.74 | ATG7 (0.47) | NAE1UBA3ATG7UBA6UBA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | NAE1 41/4885UBA3 12/4885ATG7 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.